Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Syndax Pharmaceuticals (SNDX) Shares Outstanding (Weighted Average) (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Shares Outstanding (Weighted Average) for 12 consecutive years, with $88.3 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Outstanding (Weighted Average) rose 2.42% year-over-year to $88.3 million; the TTM value through Mar 2026 reached $88.3 million, up 2.42%, while the annual FY2025 figure was $86.6 million, 1.17% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $88.3 million in Q1 2026 for Syndax Pharmaceuticals, up from $86.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $88.3 million in Q1 2026 and bottomed at $59.0 million in Q1 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $76.2 million, with a median of $85.2 million recorded in 2024.
  • Year-over-year, Shares Outstanding (Weighted Average) grew 22.72% in 2024 and then rose 1.13% in 2025.
  • Syndax Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $60.8 million in 2022, then increased by 15.82% to $70.4 million in 2023, then grew by 21.67% to $85.6 million in 2024, then increased by 1.17% to $86.6 million in 2025, then grew by 1.88% to $88.3 million in 2026.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $88.3 million, $86.6 million, and $86.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.